US OptionsDetailed Quotes
VTYX241220P4500
- 0.00
- 0.000.00%
15min DelayClose Nov 27 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest4.50Strike Price0.00Turnover140.77%IV-69.81%PremiumDec 20, 2024Expiry Date1.85Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9136Delta0.1838Gamma1.41Leverage Ratio-0.0029Theta-0.0017Rho-1.29Eff Leverage0.0010Vega
Ventyx Biosciences Stock Discussion
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
Ventyx Biosciences (Nasdaq: VTYX) presented new 52-week results from the Phase 2 trial of VTX002 (tamuzimod) in ulcerative colitis at UEG Week 2024. The late-breaking abstract highlighted high rates of clinical and endoscopic remission among long-term extension (LTE) completers at Week 52. CEO Raju Mohan emphasized the data's reinfo...
📊⚡️📊
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price...
Ventyx Biosciences Announces $27 Million Strategic Investment From Sanofi
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease
Ventyx Biosciences (Nasdaq: VTYX) has initiated dosing in a Phase 2a trial of VTX3232 for early Parkinson's disease. The trial aims to evaluate the drug's effects on disease- and target-relevant biomarkers, including exploratory PET neuroimaging to measure its impact on microglial activation. This study is based on evidence suggesting a str...
Ventyx Biosciences Inc - Vtx958 Phase 2 Trial Fails Primary Endpoint in Crohn's Disease
Positive
▪️VTX3232 monotherapy reduced body weight and food intake in DIO mice.
▪️Significant reductions in liver triglycerides and fat deposits were observed with VTX3232.
▪️Improvements in insulin resistance and cardiometabolic parameters, including reduced cholesterol, fasting blood glucose, and HbA1c.
▪️Systemic inflammatory biomarkers (IL-1β, IL-6, fibrinogen) were reduced with VTX3232.
▪️Combination of VTX3232 and semag...
No comment yet